These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23828252)

  • 1. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min.
    Auerbach M; Strauss W; Auerbach S; Rineer S; Bahrain H
    Am J Hematol; 2013 Nov; 88(11):944-7. PubMed ID: 23828252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
    Schiller B; Bhat P; Sharma A
    Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
    Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.
    Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z
    Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron indices and intravenous ferumoxytol: time to steady-state.
    Kapoian T; O'Mara NB; Carreon M; Gajary A; Rizkala A; Lefavour G; Sherman RA; Walker J
    Ann Pharmacother; 2012 Oct; 46(10):1308-14. PubMed ID: 22968523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.
    Lu M; Cohen MH; Rieves D; Pazdur R
    Am J Hematol; 2010 May; 85(5):315-9. PubMed ID: 20201089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron.
    Vadhan-Raj S; Strauss W; Ford D; Bernard K; Boccia R; Li J; Allen LF
    Am J Hematol; 2014 Jan; 89(1):7-12. PubMed ID: 23983177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
    Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
    Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study.
    Vadhan-Raj S; Ford DC; Dahl NV; Bernard K; Li Z; Allen LF; Strauss WE
    Am J Hematol; 2016 Feb; 91(2):E3-5. PubMed ID: 26572233
    [No Abstract]   [Full Text] [Related]  

  • 13. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease.
    Schwenk MH
    Pharmacotherapy; 2010 Jan; 30(1):70-9. PubMed ID: 20030475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency.
    Cohen J; Khudanyan A; Lu J; Wing J; Olson S; Deloughery T; Shatzel JJ
    Am J Hematol; 2020 Dec; 95(12):1572-1577. PubMed ID: 32918335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
    Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
    BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.
    Provenzano R; Schiller B; Rao M; Coyne D; Brenner L; Pereira BJ
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):386-93. PubMed ID: 19176796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.
    Spinowitz BS; Schwenk MH; Jacobs PM; Bolton WK; Kaplan MR; Charytan C; Galler M
    Kidney Int; 2005 Oct; 68(4):1801-7. PubMed ID: 16164657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
    Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients.
    Fishbane S; Bolton WK; Winkelmayer WC; Strauss W; Li Z; Pereira BJ
    Clin Nephrol; 2012 Sep; 78(3):181-8. PubMed ID: 22874106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.